Neoprobe Corp. and Laureate Pharma have entered into a Biopharmaceutical Development and Manufacturing Agreement under which Laureate will assist in the development and production of Neoprobe’s murine monoclonal antibody CC49. Also called RIGScan CR, CC49 is a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed. “We are delighted that Neoprobe has selected Laureate Pharma as their ...